GlassScriptPhysician profile
Nikhil Madan
NPI 1275794448
$4,030.41
in general payments reported to CMS, 2019-2025
29 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 77% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2021: $166 · 2022: $393 · 2023: $1,060 · 2024: $1,240 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.54 |
| Education | $174.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,207.35 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $378.22 | 2021-2025 | Fasenra, Tezspire |
| Astellas Pharma US INC | $316.17 | 2021-2025 | Cresemba |
| Actelion Pharmaceuticals US, INC. | $310.28 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.80 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Genzyme Corporation | $245.63 | 2022-2025 | |
| United Therapeutics Corporation | $207.42 | 2022-2025 | Orenitram, Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $145.91 | 2023-2025 | Livtencity, Glassia, Hyqvia |
| Mylan Specialty L.P. | $125.79 | 2022-2024 | Yupelri |
| Viatris Specialty LLC | $119.64 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $99.11 | 2023-2025 | Winrevair |
| Insmed, INC. | $97.32 | 2023-2024 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $71.05 | 2021-2025 | |
| Galvanize Therapeutics, INC | $58.28 | 2023 | Aliya System |
| Vifor Pharma, INC. | $51.00 | 2024 | Zemaira |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.17 | 2024 | |
| Novo Nordisk INC | $33.47 | 2024 | Wegovy |
| Amgen INC. | $31.98 | 2023-2025 | Tezspire |
| 3b Medical, INC. | $30.81 | 2024 | Luna |
| Alexion Pharmaceuticals, INC. | $26.09 | 2022 | |
| Boston Scientific Corporation | $25.45 | 2024 | |
| La Jolla Pharmaceutical Company | $24.01 | 2023 | Giapreza |
| Pulmonx Corporation | $22.91 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Cmp Pharma, INC. | $17.00 | 2023 | Tadliq, Liqrev, Atorvaliq |
| Mallinckrodt Hospital Products INC. | $15.07 | 2023 | Acthar |
| Abbvie INC. | $14.92 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.33 | 2022 | |
| Ani Pharmaceuticals, INC. | $13.39 | 2024 | Purified Cortrophin Gel |
| Akcea Therapeutics, INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Madan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.